CN114916669A - 一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 - Google Patents
一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 Download PDFInfo
- Publication number
- CN114916669A CN114916669A CN202210535785.7A CN202210535785A CN114916669A CN 114916669 A CN114916669 A CN 114916669A CN 202210535785 A CN202210535785 A CN 202210535785A CN 114916669 A CN114916669 A CN 114916669A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- health food
- extract
- salmon roe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000972773 Aulopiformes Species 0.000 title claims abstract description 72
- 235000019515 salmon Nutrition 0.000 title claims abstract description 72
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 39
- 235000013402 health food Nutrition 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 34
- 241000208340 Araliaceae Species 0.000 claims description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 28
- 235000008434 ginseng Nutrition 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 235000020712 soy bean extract Nutrition 0.000 claims description 24
- 229940087603 grape seed extract Drugs 0.000 claims description 17
- 235000002532 grape seed extract Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 10
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 10
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 241000219095 Vitis Species 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 22
- 238000012360 testing method Methods 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000032683 aging Effects 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000013589 supplement Substances 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 240000006365 Vitis vinifera Species 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 238000005502 peroxidation Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021034 Hypometabolism Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008049 biological aging Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 free radical lipid Chemical class 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/30—Fish eggs, e.g. caviar; Fish-egg substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
- Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用,它涉及保健品领域,本发明的目的是为了解决目前抗氧化保健品改善提高老年人和中青年人的生活质量和水平的抗氧化效果不佳的问题,本发明的保健品由1~200重量份人参叶提取物、1~100重量份大豆提取物、1~100重量份葡萄籽提取物和1~50重量份鲑鱼籽粉组成。将上述组分混匀后,加入辅料,制成相应剂型。本发明在传统中医理论指导下组方,兼具现代医学治疗特点,根据动物功能试验及人体试食试验验证,本产品具有明显的抗氧化功能。本发明应用于保健品领域。
Description
技术领域
本发明涉及保健食品领域,具体涉及一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用。
背景技术
衰老是生命过程中正常的生理现象,国内外学者从细胞分子水平探索生物衰老机制,提出了自由基的衰老学说,目前已发现有100多种疾病与自由基脂质过氧化损伤有关,如动脉粥样硬化、心血管疾病、糖尿病、白内障、老年痴呆、关节退行性病变、肝肾损伤等常见老年病,是主要的发病原因。人体内自由基的产生有内源性自由基及外源性自由基两个方面,内源性自由基主要由各种代谢反应产生,外源性自由基是由环境中的高温、辐射、光解、化学物质等引起的。过量的自由基是引起体内细胞、组织、器官的损伤,也是使机体生锈、导致衰老和疾病性的根源。利用外来抗氧化物的补充,帮助人体降低过多的自由基,免除不安全的自由基毒素对细胞、器官的破坏,预防衰老及消除疾病,已成为现代社会的趋势和时尚。
随着人们生活水平不断的提高,关注养生和保健的人群日趋扩大,现在市面上也有很多声称具有抗氧化功能的食疗产品,这些产品多数为将人们日常食用的含有抗氧化功能的食品,如蕃茄、菠菜、坚果、葡萄、燕麦、大蒜、蓝莓、绿茶、红酒等、维生素C或维生素E等进行无理论基础的叠加,配方用量无理论支持,各种成份间有无相互干扰无法确定,产品不良反应及抗氧化功效无临床数据验证,人们服用的安全性及有效性难以保障。
申请号CN200410081447.2名称《一种抗氧化保健食品及其制造方法》的发明专利公开了一种抗氧化保健食品,其有效成份为:95~190重量份原花青素、30~50重量份大豆异黄酮、95~200重量份维生素C、35~65重量份维生素E。其组方根据中国营养学会对膳食推荐供给量等各项指标制定,并没有考虑成份间的相互叠加及相互干扰影响,所以从长期及整体效果上无法保证新产品功效。
发明内容
本发明的目的是为了解决目前抗氧化保健品改善提高老年人和中青年人的生活质量和水平的抗氧化效果不佳问题,而提供一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用。
本发明产品以我国传统中医理论为组方指导,以人参叶提取物为君,辅以大豆提取物、葡萄籽提取物和鲑鱼籽粉。中医对人体衰老或早衰的认识源远流长,内容极其丰富,为大多数学者公认,而又有较好之实践效验者,当以肾虚致衰之说为最,肾虚致衰是肾元之阳气和肾藏之精气亏损,虚少,五脏气血津液生化无源导致的诸多衰老病态和衰老过程。肾藏精,为先天之本,生命之源,以肾为主宰、维系人体的一切生理功能,使其统一平衡从而抵御疾病,肾气亏虚则五脏之气血精津液生化乏源,各种衰老病症更日益显露出来。中医认为久病、慢性病没有不损及肾气的,所以又有“病久之疾,穷必及肾”之说。从中医理论上看,过氧化造成的人体组织衰老,从中医角度属于气阴不足,虚阳化火,人烁伤阴这样一个状态。
本发明产品配伍以人参叶提取物为君,本品苦、甘,微温。归肺脾心肾胃经,具大补元气,复脉固脱,补脾益肺,生津养血之功,以大豆提取物为臣,大豆提取物补肾强腰,填精生髓,可补充人体肾经循行的腰胯、下肢等部位的气血不足,调节代谢低下引起的乏力腿软,并能引人参叶功能下行,起到引经的作用,葡萄籽提取物为佐药,中医取类比象,认为其从阴中出阳,可通透经络,生发人体生命潜能,改善浊重的阴湿邪气郁遏而阳气不能生发造成的人体疲劳、乏力、虚火烧烁等,表现为现代医学所说的过氧化、自由基清除不畅等亚健康状态,再配以鲑鱼籽为阴中之阳,可补充人体阳气运行必要的物质基础。
从现代医学研究结果看人参提取物具有很强的抗疲劳、耐缺氧、抗应激作用,可增加红细胞SOD活性,减少脂褐质的堆积;大豆提取物有较强的抗氧化作用,能有效的预防癌症、骨质疏松和妇女更年期综合症等多种疾病的发生,大豆中含有大豆异黄酮、大豆卵磷脂等成份,可有效缓解衰老。葡萄籽提取物具有抗氧化、清除自由基、保护心血管和预防高血压等作用;鲑鱼籽粉含有丰富的维生素、蛋白质及多种矿物质能很好的补充身体流失的营养成份,在以上药味抗氧化作用的同时,为机体提供必须的营养成份。
《中国药典》规定人参叶日常用量为3~9g,可根据提取比例折算提取物的日服用剂量,大豆异黄酮的推荐日服用剂量上限为120mg,原花青素目前国内外成人的日用量一般在100~300mg,本品每日补充鲑鱼籽粉20-80mg,参照上述服用指导剂量范围,本发明公开的一种抗氧化保健食品,其特征在于其有效成份为:1~200重量份人参叶提取物、1~100重量份大豆提取物、1~100重量份葡萄籽提取物、1~50重量份鲑鱼籽粉。
在上述范围剂量下,经功能性测试结果表明其具有明显的抗氧化作用,人体试食试验表明具抗氧化作用。
本发明中的人参叶提取物、大豆提取物、葡萄籽提取物和鲑鱼籽均可以通过直接购买市售品获得。
本发明保健食品的制备方法可以为:取所述重量份的鲑鱼籽冷冻干燥、人参叶提取物、大豆提取物、葡萄籽提取物,分别过筛,混匀,制粒或不制粒,加入或不加辅料按照常规工艺制备成药剂学上任意一种剂型。
所述的剂型可以为颗粒剂、胶囊剂(硬胶囊、软胶囊)、片剂(普通片、分散片、口腔崩解片、含片、咀嚼片、泡腾片)或口服液体制剂及其他一切可以接受的剂型。
鱼籽是一种营养丰富的食品,其中含有大量的蛋白质、钙、磷、铁、维生素和核黄素,鱼籽中磷酸盐的平均含量达到46%以上,是人脑及骨髓的良好滋补品,丰富的维生素类也能增强人体抗氧化功能,鱼籽在协同抗氧化的同时,还会帮助补充人体所需的各种营养物质,因此非常适合用于配制本发明抗氧化保健食品,本发明选取新鲜的鲑鱼(俗称大马哈鱼)鱼籽。
本发明包含以下有益效果:
本发明在传统中医理论指导下组方,兼具现代医学治疗特点,根据动物功能试验及人体试食试验验证,本产品具有明显的抗氧化功能。原料药中的人参叶有很强的抗缺氧作用,并且能够增加经细胞的SOD活性,大豆可以补充适量雌激素,调节荷尔蒙平衡,使皮肤保持弹性,减轻女性更年期的衰老症状,配以天然的抗氧化葡萄籽提取物能够更好的清除体内的自由基,鱼籽能够更好的补充身体缺失的营养物质,将对中老年人的机体衰老起到明显的调节作用。
本品将中医理论应用到保健食品的研发当中,在中医理论的指导下,以人参叶为君药,人参叶的作用较人参温和,偏于补益,可纠正人体气阴不足,虚阳化火、火烁伤阴的状态,并有养血、补胃气、泻心火,调中治气,也可以消食开胃,也可以治脾胃阳气不足、肺气促、短气、少气,最后可以补中、缓中,可以解肺脾、胃中、活血等。以大豆提取物为臣,大豆提取物补肾强腰,填精生髓,可补充人体肾经循行的腰胯、下肢等部位的气血不足,调节代谢低下引起的乏力腿软,并能引人参叶功能下行,起到引经的作用,葡萄籽提取物为佐药,中医取类比象,认为其从阴中出阳,可通透经络,生发人体生命潜能,改善浊重的阴湿邪气郁遏而阳气不能生发造成的人体疲劳、乏力、虚火烧烁等,表现为现代医学所说的过氧化、自由基清除不畅等亚健康状态,再配以鲑鱼籽为阴中之阳,可补充人体阳气运行必要的物质基础。
本发明的保健品疗效确切、安全、无任何毒副作用,且可通过缓解老年人和中青年人机体的衰老过程,清除体内的自由基,从而改善提高老年人和中青年人的生活质量和水平的抗氧化保健食品。
人们随着年年龄的增长,整体功能的衰老表现为机体自稳态调节范围变窄,反应力、适应力、免疫力和贮备力下降,个别器官甚至功能丧失。结构的变化是细胞萎缩、数量减少、细胞内脂褐素沉积,细胞间质增多,组织纤维化在硬化,致使器官体积缩小,重量减轻,从而引起各器官系统功能的退变,本品的研制,可以清除体内自由基,改善心脑缺氧状态,促进机体状态向健康的方向转化,提高生活和学习质量。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚明白,下面将详细叙述本发明所揭示内容的精神,任何所属技术领域技术人员在了解本发明内容的实施例后,当可由本发明内容所教示的技术,加以改变及修饰,其并不脱离本发明内容的精神与范围。
本发明的示意性实施例及其说明用于解释本发明,但并不作为对本发明的限定。
实施例1:
1)制备鲑鱼籽粉:
将鲑鱼籽原料漂洗二次干净后,喷淋95%的乙醇,将乙醇淋洗过的鲑鱼籽在40~45℃的低温条件下干燥25分钟;将低温干燥后的鲑鱼籽在温度-30℃,压力12.5Pa的条件下低温冻干24小时,至水份含量为10~15%。将干燥后的鲑鱼籽进行粉碎过60目后即得。(此方法所制取的鲑鱼籽粉中蛋白质的含量约达80%以上)
咀嚼片的制备:取以步骤1)所述方法得到的鲑鱼籽粉120克、市售采购的人参叶提取物1000克、大豆提取物200克、葡萄籽提取物200克,加入蔗糖、木糖醇、羧甲基淀粉钠等辅料均匀混合,以80%的乙醇制粒,干燥、加入硬脂酸镁后压片,包装即得抗氧化保健食品咀嚼片。
实施例2:
1)制备鲑鱼籽粉:
将鲑鱼籽原料漂洗二次干净后,喷淋95%的乙醇,将乙醇淋洗过的鲑鱼籽在30~40℃的低温条件下干燥30分钟;将低温干燥后的鲑鱼籽在温度-32℃,压力13.3Pa的条件下低温冻干24小时,至水份含量为5~10%。将干燥后的鲑鱼籽进行粉碎过60目后即得。(此方法所制取的鲑鱼籽粉中蛋白质的含量约达80%以上)
2)胶囊剂的制备:取以步骤1)所述方法得到的鲑鱼籽粉150克、市售采购的人参叶提取物1000克、大豆提取物300克、葡萄籽提取物300克,加入玉米淀粉、微晶纤维素、硬脂酸镁等辅料均匀混合,灌装于0号胶囊中,包装即得抗氧化保健食品胶囊剂。
实施例3:
1)制备鲑鱼籽粉:
将鲑鱼籽原料漂洗二次干净后,喷淋90%的乙醇,将乙醇淋洗过的鲑鱼籽在30~40℃的低温条件下干燥30分钟;将低温干燥后的鲑鱼籽在温度-29℃,压力14Pa的条件下低温冻干24小时,至水份含量为5~10%。将干燥后的鲑鱼籽进行粉碎过60目后即得。(此方法所制取的鲑鱼籽粉中蛋白质的含量约达80%以上)
2)颗粒剂的制备:取以步骤1)所述方法得到的鲑鱼籽粉100克、市售采购的人参叶提取物1500克、大豆提取物200克、葡萄籽提取物100克,加入糖粉、麦芽糊精、羟丙甲基纤维素、香精等辅料均匀混合,以75%乙醇制粒,干燥、包装即得抗氧化保健食品颗粒剂。
实施例4:
1)制备鲑鱼籽粉:
将鲑鱼籽原料漂洗二次干净后,喷淋75%的乙醇,将乙醇淋洗过的鲑鱼籽在30~40℃的低温条件下干燥30分钟;将低温干燥后的鲑鱼籽在温度-30℃,压力12.8Pa的条件下低温冻干24小时,至水份含量为10~15%。将干燥后的鲑鱼籽进行粉碎过60目后即得。(此方法所制取的鲑鱼籽粉中蛋白质的含量约达80%以上)
2)乳剂的制备
(1)油相的制备:向大豆油中加入大豆磷脂、泊洛沙姆、鲑鱼籽粉100克,大豆提取物200克,充分搅拌后置于水浴中恒温至60℃;
(2)水相的制备:向水中加入油酸钠、海藻酸钠、人参叶提取物800克、葡萄籽提取物200克,充分搅拌后置于水浴中恒温至70℃;
(3)乳剂的制备:将所述水相置于组织捣碎机中,在4000r/min的条件下将所述油相缓慢加入所述水相中,边加入边搅拌,全部加入后继续以上述条件搅拌5min;加水至全量后继续搅拌10min,放凉后充氮灌装,105℃灭菌30min,即得抗氧化保健食品乳剂。
实施例5:
为验证本保健食品的抗氧化功能,按自愿原则选择45-65岁,身体健康状况良好,无明显脑、心、肝、肾、血液疾病,无长期服药史的250例受试者,按MDA、SOD水平随机分为试食组和对照组,试食组1-4组分别服用实例1-4的工艺制备成相应的剂型。,每次2粒,每日2次,服用90天,对照组为空白对照;观察试食组主要临床症状:疲劳感、烦燥、健忘、睡眠、腰酸膝痛等。并观察试食组与对照组试食前后MDA及SOD的变化及升高百分率,本抗氧化保健食品试用效果及对照情况表如下:
表1试食前后各指标成份对照表(X±SD)
结论:本产品SOD是升百分率为13.18%,自身对照有显著性差异;与对照组比较有显著性差异;MDA下降百分率为27.49%,自身对照有显著性差异;与对照组比较有显著性差异,说明本产品具有明显的抗氧化功能,本品对受试者的疲劳感、烦燥、健忘、睡眠、腰酸膝软等症状有改善作用,本品试食后未见明过敏及其他不良反应。
实施例6:
为验证本品的安全性能,按《保健食品检验与评价技术规范》中保健食品安全性毒理学评价程序和检验方法规范进行急性毒性试验,观察受试样品一次经口给予动物引起的不良反应及死亡情况并确定半数致死剂量(LD50)或最大耐受剂量(MTD)。禁食16小时后,按体重要求选取雌雄小鼠各10只,将受试样品(按实例1制备的胶囊剂)采用最大耐受剂量法对实验动物染毒,染毒后,观察动物的一般状态,体重变化,中毒症状和死亡情况等,观察期为一周。试验结果如下:
表3雌雄小鼠急性经口毒性试验结果
结果表明:试验期间各组动物活动正常,毛色光泽度好,未见任何中毒症状和死亡,到期处死动物,大体解剖肉眼观察各脏器情况良好,未见异常。
实施例7
为证明本发明保健品配伍的合理性,本实施例采用DPPH自由基清除法及水杨酸分析法对不同处方组成进行了体外抗氧化实验,结果如下(以下处方为制成2000粒用量):
处方1:人参叶提取物200克、大豆提取物200克、葡萄籽提取物200克,鲑鱼籽粉120克。
处方2:大豆提取物200克、葡萄籽提取物200克、鲑鱼籽粉120克。
处方3:人参叶提取物200克、葡萄籽提取物200克、鲑鱼籽粉120克。
处方4:人参叶提取物200克、大豆提取物200克、鲑鱼籽粉120克。
处方5:人参叶提取物200克、大豆提取物200克、葡萄籽提取物200克。
上述处方1至5按照实施例1的方法制备保健品。
表1不同处方清除DPPH自由基的能力
处方 | 处方1 | 处方2 | 处方3 | 处方4 | 处方5 |
清除能力 | 83.57% | 47.32% | 59.43% | 54.11% | 64.51% |
表2不同处方羟自由基清除能力
处方 | 处方1 | 处方2 | 处方3 | 处方4 | 处方5 |
清除能力 | 79.26% | 44.32% | 56.85% | 52.65% | 62.49% |
由以上实验数据可以看出,本处方中君臣佐使缺一不可,4种物质相辅相成,协同加强产生清除自由基及抗氧化效果,配伍效果远大于其他任意三种成份的组合。
实施例8
为证明本发明保健品原料选取的合理性,本实施例继续采用DPPH自由基清除法及水杨酸分析法对不同鱼籽处方组成进行了体外抗氧化实验,结果如下(以下处方为制成2000粒用量):
处方1:人参叶提取物200克、大豆提取物200克、葡萄籽提取物200克,鲑鱼籽粉120克。
处方2:人参叶提取物200克、大豆提取物200克、葡萄籽提取物200克,鲟鱼籽粉120克。
处方3:人参叶提取物200克、大豆提取物200克、葡萄籽提取物200克,多春鱼籽粉120克。
表1不同处方清除DPPH自由基的能力
处方 | 处方1 | 处方2 | 处方3 |
清除能力 | 83.57% | 52.32% | 48.43% |
表2不同处方羟自由基清除能力
处方 | 处方1 | 处方2 | 处方3 |
清除能力 | 79.26% | 46.32% | 41.85% |
由以上实验数据可以看出,对其他二种类型的鱼籽相比较,鲑鱼籽在本发明中可以与诸药起到良好的抗氧化作用,鲑鱼籽性质偏温,营养成份更加丰富,取阴中之阳,为人体气血运行提供必要的物质基础,促进气血运行周身,加速机体的新陈代谢,与诸药联合加强抗氧化功效。
Claims (10)
1.一种含鲑鱼籽的抗氧化保健食品,其特征在于它是由1~200重量份人参叶提取物、1~100重量份大豆提取物、1~100重量份葡萄籽提取物和1~50重量份鲑鱼籽粉组成。
2.根据权利要求1所述的一种含鲑鱼籽的抗氧化保健食品,其特征在于所述的保健食品是由10~150重量份人参叶提取物、10~80重量份大豆提取物、10~80重量份葡萄籽提取物和5~40重量份鲑鱼籽粉组成。
3.根据权利要求1或2所述的一种含鲑鱼籽的抗氧化保健食品,其特征在于所述的保健食品是由20~100重量份人参叶提取物、20~60重量份大豆提取物、20~60重量份葡萄籽提取物和10~30重量份鲑鱼籽粉组成。
4.根据权利要求1或2所述的一种含鲑鱼籽的抗氧化保健食品,其特征在于所述的保健食品是由30~80重量份人参叶提取物、30~50重量份大豆提取物、30~50重量份葡萄籽提取物和20~30重量份鲑鱼籽粉组成。
5.根据权利要求4所述的一种含鲑鱼籽的抗氧化保健食品,其特征在于于所述的保健食品是由40~60重量份人参叶提取物、40~50重量份大豆提取物、40~50重量份葡萄籽提取物和20~30重量份鲑鱼籽粉组成。
6.根据权利要求1或5所述的一种含鲑鱼籽的抗氧化保健食品,其特征在于所述的鲑鱼籽粉的蛋白质含量为80%以上。
7.制备权利要求1所述的一种含鲑鱼籽的抗氧化保健食品的方法,其特征在于它是按照以下内容进行的:
将称取的1~200重量份人参叶提取物、1~100重量份大豆提取物、1~100重量份葡萄籽提取物和1~50重量份鲑鱼籽粉混合均匀后,加入辅料混合,过筛,制成相应的剂型,即得所述的含鲑鱼籽的抗氧化保健食品。
8.根据权利要求7所述的一种含鲑鱼籽的抗氧化保健食品的方法,其特征在于所述的鲑鱼籽粉的制备方法如下:
1)将鲑鱼籽原料漂洗干净后,喷淋体积浓度为40%~95%的乙醇;
2)将乙醇喷淋过的鲑鱼籽在25~50℃的温度条件下干燥5-60min;
3)将干燥后的鲑鱼籽在温度-10~-40℃、压力10~15Pa的条件下低温冻干至水份含量为3~15%;
4)将干燥后的鲑鱼籽进行粉碎后即得鲑鱼籽粉。
9.根据权利要求7所述的一种含鲑鱼籽的抗氧化保健食品的方法,其特征在于所述的鲑鱼籽粉的蛋白质含量为80%以上。
10.如权利要求1所述的一种含鲑鱼籽的抗氧化保健食品应用,其特征在于它作为用于改善提高老年人和中青年人的生活质量和水平的保健品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210535785.7A CN114916669A (zh) | 2022-05-17 | 2022-05-17 | 一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210535785.7A CN114916669A (zh) | 2022-05-17 | 2022-05-17 | 一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114916669A true CN114916669A (zh) | 2022-08-19 |
Family
ID=82809271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210535785.7A Pending CN114916669A (zh) | 2022-05-17 | 2022-05-17 | 一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114916669A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101019916A (zh) * | 2006-07-28 | 2007-08-22 | 李富民 | 脱脂鲑鱼卵(大马哈鱼籽)粉女性保健食品及其制备方法 |
CN114901082A (zh) * | 2019-12-26 | 2022-08-12 | 玛鲁哈日鲁株式会社 | 包含键合有多元不饱和脂肪酸的磷脂的鱼卵脂质组合物 |
-
2022
- 2022-05-17 CN CN202210535785.7A patent/CN114916669A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101019916A (zh) * | 2006-07-28 | 2007-08-22 | 李富民 | 脱脂鲑鱼卵(大马哈鱼籽)粉女性保健食品及其制备方法 |
CN114901082A (zh) * | 2019-12-26 | 2022-08-12 | 玛鲁哈日鲁株式会社 | 包含键合有多元不饱和脂肪酸的磷脂的鱼卵脂质组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190328817A1 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
CN109700011A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN107373672A (zh) | 一种月经不调女性专用型临床营养配方及其制备方法 | |
CN112704223A (zh) | 一种具有辅助保护胃黏膜作用的组合物及其应用、保健食品 | |
CN101766274A (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
CN110960624A (zh) | 一种抗疲劳的组合物及其制备方法 | |
KR20150087968A (ko) | 노화 및 관절염의 예방 또는 치료용 조성물 | |
KR101642176B1 (ko) | 성장촉진 조성물 | |
CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 | |
US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
CN111407850A (zh) | 植物硒黄精片及其制备方法 | |
WO2020089831A1 (en) | Phyto-therapyc compositions useful to improve the quality of sleep and in the treatment of insonnia, anxiety and depression | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN108617779A (zh) | 一种对化学性肝损伤有辅助保护作用的驼奶组合物 | |
CN114916669A (zh) | 一种含鲑鱼籽的抗氧化保健食品及其制备方法和应用 | |
CN106036894B (zh) | 一种改善癌症患者化疗症状的食品组合物及其制备方法 | |
KR102439576B1 (ko) | 뇌기능 개선용 영양전달체 조성물 | |
CN103798596B (zh) | 一种供心脑血管疾病患者食用的全营养配方食品 | |
CN105412391A (zh) | 辅助抗氧化功能的保健食品组方及制备方法 | |
Ravash et al. | The effect of hydroalcoholic extracts from Taraxacum officinale on blood indicators of kidney and liver functions in male rats | |
CN108968066A (zh) | 一种增强免疫力的人参、白术、茯苓、枸杞子的药膳素产品及其制备方法 | |
CN101347483A (zh) | 一种治疗肠胃病的中草药组合物及其制备方法和用途 | |
CN106108016A (zh) | 一种缓解体力疲劳的保健食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |